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Endoscopic ultrasonography (EUS)-guided translumenal drainage of pancreatic ﬂuid collections and obstructed bile and pancreatic ducts has been widely
practiced for over a decade now, using conventional tubular plastic and metal stents. Their application for transmural drainage has been “off label” and
limited by the lack of lumen-to-lumen anchorage that can lead to leakage, perforation, and stent migration. In addition, the length of a tubular stent
exceeding the anatomical requirement of a translumenal anastomosis can lead to tissue trauma at the stent ends. Novel stent designs dedicated to
applications of translumenal drainage have recently emerged and promise to make transmural drainage quicker, safer, and more effective. Importantly,
passage of an endoscope through a translumenal stent will enable the endoscopist to expand the frontier of endoscopic intervention to structures outside
of the gastrointestinal tract.
Copyright  2015, Society of Gastrointestinal Intervention. Published by Elsevier.
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A new era in therapeutic endoscopy began with the ﬁrst endo-
scopic biliary stent placement by Soehendra and Reynders-Frederix
in 1979,1 5 years after the ﬁrst sphincterotomy. Subsequently, an
array of plastic stents with various conﬁgurations was commer-
cialized. Plastic stents have been limited by clogging, which typi-
cally occurs 3–4 months postinsertion, and migration. The
observation that an increase in stent diameter produces increased
patency rates led to the development of self-expandable metal
stents (SEMS). Randomized controlled trials comparing expandable
metallic stents with plastic stents have demonstrated signiﬁcantly
lower rates of stent obstruction and cholangitis.2,3 Nonetheless,
SEMS also occlude over time, mainly due to tumor ingrowth and/or
overgrowth and mucosal hyperplasia induced by a chronic in-
ﬂammatory reaction to the stent mesh.3 The covering of SEMS has
made these removable for the treatment of benign disease, how-
ever, these have a higher propensity to migration.
With the emergence of interventional endoscopic ultrasonog-
raphy (EUS), translumenal drainage of the bile and pancreatic
ducts, and associated ﬂuid collections such as bilomas4 and
pancreatic ﬂuid collections, has become part of the realm of the
interventional endoscopist. The linear array echoendoscope, which
enables real-time ultrasound visualization of a tool pushed out of
the accessory channel, extends the reach of endoscopic interven-
tion to targets outside of the gut wall. The development of EUS-
guided translumenal interventions has required the rapid1Waikato Hospital, Waikato District Health Board, Hamilton, New Zealand
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will cover the development of specialized stents for translumenal
access and therapy.
General considerations
Speciﬁc stent designs for translumenal intervention are inﬂu-
enced by several considerations. First is the location of the target to
be drained. This may be directly adjacent to the bowel wall or
further removed within an organ such as the liver or pancreas.
Second is the adherence of the target to the bowel wall. Third is the
therapeutic intent, which may include speciﬁc extralumenal in-
terventions such as necrosectomy for walled-off pancreatic necro-
sis and removal of stones in the gallbladder, bile, or pancreatic
ducts.
Lumenal versus translumenal stents
Conventional lumenal stents used in endoscopy are tubular in
form, conceived for coaxial placement within a lumen. The most
common indication for stenting is lumen recanalization to relieve
an obstruction due to a malignant or benign stricture.3 Stents have
also been placed to treat ﬁstulas and leaks.
Whether plastic or metal, tubular stents have several limitations
when applied to translumenal drainage. Firstly, they do not impart
lumen-to-lumen anchorage. This may result in leakage of contents
if there is physical separation of the lumens. Secondly, stente 600, San Francisco, CA 94115, USA
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place. Thirdly, the length of tubular stents exceeds the anatomical
requirement of a shorter translumenal anastomosis. The exposed
stent ends may cause tissue trauma, resulting in bleeding or
perforation. Finally, the longer the stent length, the more prone the
stent is to clogging.
A translumenal stent of sufﬁcient diameter should enable the
passage of an endoscope into the target lumen for endoscopic in-
terventions. The stent thereby serves as both a conduit for drainage
as well as an access port. This extends the array of potential in-
terventions to those routinely performed in the bowel lumen, such
as tumor resection and ablation. In the gallbladder and bile duct,
biliary interventions for stone disease, such as mechanical and
electrohydraulic lithotripsy under direct endoscopic guidance,
should be possible.Fig. 2. The handle of the AXIOS delivery system is Luer-locked onto the echoendo-
scope instrumentation channel inlet port, analogous to a standard ﬁne needle aspi-
ration needle. The handle consists of a distal portion for catheter control and a
proximal portion for stent control.Lumen-apposing stents
AXIOS
The development of a lumen-apposing stent designed for
translumenal drainagewas ﬁrst reported by Binmoeller and Shah in
2011.5 The AXIOS stent (Xlumena Inc., Mountain View, CA, USA)
consists of double-walled ﬂanges that are perpendicular to the
lumen and hold the tissue walls in apposition (Fig. 1). Fully
expanded, the ﬂange diameter is approximately twice that of the
stent lumen. Lumen diameters are 10 mm, 15 mm, and 20 mm. The
stent ﬂanges are designed to distribute pressure evenly on the
lumenal wall. The stent is made of braided nitinol wire and fully
covered to prevent tissue ingrowth and tract leakage, as well as
enable removability.
The AXIOS stent is delivered through a 10.8F catheter. Pre-
liminary tract dilation by bougienage, balloon dilation, or cautery is
needed to enable advancement of the catheter across tissue planes
into the target lumen. A tapered “nosecone” at the catheter tip
facilitates passage across the wall after this dilation has occurred.
Two radiopaque markers on the catheter indicate each end of the
preloaded stent to enable ﬂuoroscopic control of stent position, if
needed. An endoscopically visible marker identiﬁes the point at
which the proximal stent anchor should be released from the de-
livery catheter.
The handle of the AXIOS delivery system is Luer-locked onto
the echoendoscope instrumentation channel inlet port, analogousFig. 1. The AXIOS stent (Xlumena Inc., Mountain View, CA, USA) consists of double-
walled ﬂanges that are perpendicular to the lumen and hold the tissue walls in
apposition.to a standard ﬁne needle aspiration needle (Fig. 2). This gives the
operator full control of stent deployment with the right hand
alone. The handle consists of a distal portion for catheter control
and a proximal portion for stent control. Advancement of the
“catheter control hub” along the distal portion advances the
catheter into the target lumen. The desired intraluminal catheter
position is then secured in place by activating the “catheter lock”.
Retraction of the “stent deployment hub” to the halfway mark
retracts the catheter sheath to deploy the distal stent anchor in
the target lumen. The “catheter lock” is then released to retract
the “catheter control hub” until the distal anchor engages the wall
of the target lumen. Complete retraction of the “stent deployment
hub” deploys the proximal anchor in the bowel lumen. A unique
feature of the delivery system is the ability to deploy the distal
and proximal stent anchors independent of one another in two
sequential steps, with a full “stop” after the release of the distal
anchor to prevent unintended deployment of the proximal
anchor.
An evolutionary modiﬁcation of the AXIOS delivery system is
the integration of cautery into the nosecone at the catheter tip (HotFig. 3. Tip of the 10.8Fr Hot AXIOS catheter. Two radially distributed diathermic wires
converge around the guide wire lumen. The catheter houses the AXIOS stent for im-
mediate deployment after entry into the target lumen.
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around the guide wire lumen to optimize current density, to pro-
vide a clean, sharp cut with minimal coagulation effect. Cautery
enables transmural advancement of the stent delivery catheter into
the target lumenwithout preliminary tract dilation. This minimizes
or eliminates over-the-wire exchanges of instruments during
which wire access can be lost and leakage can occur. The Hot AXIOS
catheter can be inserted over-the-wire after puncture of the target
site with a 19G ﬁne needle aspiration needle and through-the-
needle wire placement, or used “freestyle” to directly access the
target lumen (Video 1). Freestyle access has the advantage of
enabling a one-step access and stent deployment procedure,
eliminating over-the-wire exchange entirely.
Supplementary video related to this article can be found online
at http://dx.doi.org/10.1016/j.gii.2015.03.003.
The AXIOS stent has been evaluated in animal studies for various
translumenal applications. A cholecystoenterostomy was created
under EUS guidance in four survival pigs.5 The stents retained their
position without inducing pressure injury or a hyperplastic tissue
reaction over a 1-month animal survival period. Contrast injection
after stent deployment showed no leakage of contrast outside of
the ﬁstula tract. The stent covering prevented ingrowth through the
mesh, making removal easy using a snare tightened over the saddle
portion. Necropsy showed fusion of the gallbladder and stomach
walls at the site of the cholecystogastrostomy and a leak-free ﬁstula
tract.
Spaxus
The Niti-S Spaxus stent7 (Taewoong Medical Co., Ltd., Ilsan,
Korea) is made of nitinol wire and fully covered with a silicone
membrane (Fig. 4). The diameter of the ﬂange at both ends is
25 mm. After deployment, the ﬂanges are folded back to hold the
two luminal interfaces in apposition. The available diameters of the
stent are 8 mm, 10 mm, and 16 mm, and the length is 20 mm, but
the distance between the ﬂanges is 5 mm after folding back with
deployment. The margin of the ﬂange is designed to transmit even
pressure on the luminal wall. This stent is delivered with a 10FFig. 4. Niti-S Spaxus stent (Taewoong Medical Co., Ltd, Ilsan, Korea) has folding-back
anchoring ﬂanges for lumen apposition.conventional delivery system. There is a blue marker on the outer
sheath to conﬁrm the complete deployment of the distal ﬂange.
Short ﬂared stents
NAGI stent
Short fully-covered SEMS with ﬂared ends to prevent migration
have been used to drain pancreatic ﬂuid collections. The NAGI
stent8 (Taewoong-Medical Co.) comes in lengths of 10 mm, 20 mm,
and 30 mm and diameters of 10 mm, 14 mm, 12 mm, and 16 mm,
with ﬂared ends of 20 mm (Fig. 5). A suture is attached at the distal
ﬂange to remove the stent.Aixstent
The pancreatic Aixstent9 (LeufenMedical, Aachen, Germany) is a
fully covered metal stent with wide ﬂanges on each end to prevent
migration. The ﬂanges have an atraumatic folded-wire design to
prevent tissue damage from the ends of the stent. The stent is
30 mm in length with a diameter of 10 mm or 15 mm and 25 mm
wide ﬂanges. This stent is currently only commercially available in
Europe.
Translumenal endoscopic interventions
Peripancreatic ﬂuid collections
Peripancreatic ﬂuid collections (PFCs) may complicate the
course of acute or chronic pancreatitis or pancreatic surgery. The
revised Atlanta classiﬁcation10 reﬂects the importance of differen-
tiating ﬂuid from nonliqueﬁed collections (“walled-off necroses”)
as the therapeutic strategy and clinical outcome differ. Whether the
collection is infected or sterile also affects the need for intervention.
PFCs that lack adherence to the enteric wall have been histori-
cally considered a contraindication to endoscopic translumenal
drainage, owing to an inherent risk of displacement during
instrumentation that can result in cyst and/or enteric leakage or
perforation into the retroperitoneum. We reported on the insertion
of a conventional 10 mm  40 mm biliary fully-covered SEMS
(Wallﬂex; Boston Scientiﬁc, Natick, MA, USA) without prior tractFig. 5. The NAGI stent (Taewoong-Medical Co., Ltd, Ilsan, Korea) has strongly ﬂared
ends to prevent migration. A suture is attached at the distal ﬂange to remove the stent.
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removed 7–10 days after insertion and exchanged for two or three
10Fr  3 cm long double-pigtail stents. For PFCs that contained
necrosis and required debridement, balloon dilation of the tract to
12–15 mm was performed followed by endoscopy-guided
debridement with an adult gastroscope. A limitation of the
10 mm stent was the inability to immediately access the PFC with
an adult endoscope after insertion, due to the small diameter. The
lack of ﬂared ends risks premature stent dislodgement that may be
complicated by leak and dehiscence of a poorly adherent ﬂuid
collection. Outwardmigration can occur resulting in premature loss
of drainage, and inward migration into the ﬂuid collection has been
reported.12
Through-the-scope deployment of a 18 mm  60 mm, fully-
covered esophageal nitinol stent with 26-mm diameter ﬂanges
(antimigration property) (Niti-S SEMS; Taewoong-Medical Co.) was
reported by Attam et al13 and Saxena et al14 in two case series (15
patients). Attam et al13 reported a 20% stent migration rate and 30%
delayed reintervention for endoscopic translumenal necrosectomy
(ETN), which was not attempted at initial procedure. Saxena et al14
placed an additional double pigtail stent through the stent lumen to
prevent migration and did not require ETN.
Use of the short ﬂared NAGI stent was reported in several case
series with good clinical utility.8,15,16 However, more recently
Chandran et al17 reported a signiﬁcant stent dysfunction rate of
24.1%. This consisted of stent maldeployment at initial delivery
(7.4%), inward migration (1.9%) delayed stent migration (11.1%), as
well as stent ingrowth preventing stent removal in 3.7%.
Itoi et al18 described the use of the AXIOS lumen-apposing stent
to provide an immediate conduit to access the PFC at index pro-
cedure and for serial necrosectomy (Fig. 6). In clinical studies, the
AXIOS stent lumen was found to be easily intubated with the
endoscope and to stabilize the endoscope during manipulation,
including retroﬂexion, without dislodgement.19 Gornals et al20 and
Parra et al21 also reported individual cases of multiple SEMS to
create multiple gateway access for drainage and intervention to
allow prompt resolution of complex collections.
Moon et al7 described the use of the SPAXUS lumen-apposing
stent in four patients (only one with a complex collection) with
good symptoms resolution in all patients after 2–10 days and
removal of the stent after a median in situ time of 26 days. The stent
lumen allowed insertion of a gastroscope for endoscopic visuali-
zation, tissue biopsy, and necrosectomy.Fig. 6. AXIOS stent used as a conduit to access a pancreatic ﬂuid collection for
necrosectomy using a net basket.Cholecystostomy
The gallbladder can be visualized under EUS-guidance from the
gastric antrum or transduodenally. Internal drainage of the gall-
bladder into the bowel lumen is conceptually no different to
pseudocyst drainage. However, unlike a pseudocyst, the non-
inﬂamed gallbladder is not adherent to the bowel wall. Therefore,
additional precautions are required to minimize the risk of bile and
gas leakage.
EUS-guided gallbladder drainage (EUS-GBD) has been compared
to percutaneous transhepatic gallbladder drainage (PTGBD)
without differences in terms of its safety and feasibility, but with
signiﬁcantly less postprocedural pain.22 EUS-GBD avoids compli-
cations unique to PTGBD, such as hepatic hematoma and pneu-
mothorax. In addition, internal drainage by the transmural
approach can be performed in patients with perihepatic ascites that
otherwise would be a contraindication to PTGBD.
Chronic inﬂammation of the gallbladder usually results in
adherence to the gut wall, making gallbladder drainage similar to
pseudocyst drainage. Kwan et al23 described gallbladder drainage
using conventional pigtail stents and nasobiliary catheters with
effective resolution of cholecystitis. Jang et al24 used a modiﬁed
partially covered tubular SEMS design (BONA-AL Stent, Standard
Sci Tech Inc, Seoul, Korea) to reduce inward/outward migration
with excellent outcomes. Observational studies show high tech-
nical and clinical success, especially when used as a bridge to
formal cholecystectomy. Complications include bile leakage and
pneumoperitoneum, which usually responds to conservative
management. Bile and air leakage after stent placement can be
minimized by initial placement of a nasobiliary drainage catheter
through the stent or placement of a fully covered SEMS.23–25
Use of a lumen-apposing stent reduces the risk of bile and gas
leakage when adherence is lacking or indeterminate. Itoi et al18
described the use of the AXIOS lumen-apposing stent in ﬁve pa-
tients presenting with acute cholecystitis with clinical success in
all. De la Serna-Higuera et al26 reported technical success in 11/13
patients who underwent gallbladder drainage using the AXIOS
stent. Of these 11 patients, direct endoscopic intervention was
performed in six patients using a standard or ultra slim endo-
scope, introduced into the gallbladder via the stent lumen to
aspirate pus, stone or sludge removal and for lavage. Del la Serna-
Higuera et al26 left the AXIOS stent in situ as a deﬁnitive treatment
strategy in 10/11 patients due to underlying comorbidities,
without further recurrence of symptoms during a median follow-
up of 101 days.
Using the Hot AXIOS platform with single-step puncture and
stent delivery, Teoh et al6 reported a case of EUS-GBD in a patient
with ongoing sepsis, despite prior percutaneous drainage. The
gallbladder was directly punctured by “freestyle”, using cautery to
assist the puncture, without prior Foley or guidewire insertion. The
authors noted excellent maneuverability and visibility of the de-
livery system under EUS-guidance.
The Spaxus lumen-apposing stent has been used in pigs and
three patients (bile duct and gallbladder cancer) with resolution of
symptoms.7 The stents were left in situ during a median follow-up
of 5 months.
Hepatogastric biliary drainage
The left intrahepatic duct can be accessed with EUS from the
proximal stomach, and occasionally from the distal esophagus,
depending on individual anatomy, enabling hepatogastric biliary
drainage. In the postgastrectomy patient, the intrahepatic ducts
may be accessible from the proximal jejunum. Hepatogastric
drainage may be the only option for internal drainage in patients
Fig. 7. AXIOS stent for choledochoduodenostomy. (A) Endoscopic view of bile draining through stent after deployment in the duodenal bulb. (B) Used as a conduit to access the bile
duct for cholangioscopy.
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biliary SEMS placement. Lack of extrahepatic bile duct access (e.g.,
altered surgical anatomy or duodenal obstruction) is a further
indication for hepatogastric drainage.
The risk of bile leakage into the peritoneum is theoretically
lower with a transhepatic access, owing to the surrounding liver
parenchyma that may tamponade the ductal puncture site andmay
act as a “sponge” for bile leak. This is consistent with experience
with percutaneous transhepatic biliary drainage by interventional
radiologists, and why preference is sometimes given to a trans-
hepatic rather than free peritoneal access for drainage of the gall-
bladder.27 However, due to nonadherence of the liver to the
stomach wall and constant movement between the two organs,
fatal migration or dislodgement of a transhepatic stent can occur.28
Isayama et al29 observed proximal stent migration in two of ﬁve
patients after hepatogastric placement of an 8-cm fully-covered
SEMS versus no migration in 10 patients treated with a 12-cm
SEMS (1-cm uncovered at the hepatic end), suggesting that the
intragastric portion needs to be at least 4 cm or longer. Giovannini
et al30 reported use of an 8 cm or 10 cm half-covered stent (at the
gastric end, with a ﬂared ﬂange) in 22 patients with resolution of
jaundice in 21 patients, but with an 18% cholangitis rate in the 1st
month due to stent obstruction. The stent has a radiological marker
visible on ﬂuoroscopy at the transition zone of stent covering to
guide placement of the uncovered portion within the liver, but
stent shortening and migration may alter the position of the un-
covered position.
Choledochoduodenostomy
The common bile duct is usually accessed and drained from the
duodenal bulb, although access from the stomach antrum has been
reported.31–33 Early experience with plastic stents34 was compli-
cated by bile leakage and abandoned in preference for fully covered
SEMS.33,35 The AXIOS stent has been custom designed for this
purpose with diameters of 6 mm and 8 mm and saddle length of
8 mm36 (Fig. 7A). Additionally, the stent serves as an access port for
direct cholangioscopy and endoscopy-guided therapy (Fig. 7B).
Conclusion
EUS-guided translumenal drainage of pancreatic ﬂuid collec-
tions and obstructed bile and pancreatic ducts has been widelypracticed for over a decade now, using conventional tubular plastic
and metal stents. Their application for transmural drainage has
been “off label” and limited by the lack of lumen-to-lumen
anchorage that can lead to leakage and stent migration. In addi-
tion, the length of a tubular stent exceeding the anatomical
requirement of a translumenal anastomosis can lead to tissue
trauma at the stent ends. Novel stent designs dedicated to appli-
cations of translumenal drainage have recently emerged and
promise to make transmural drainage quicker, safer, and more
effective. Importantly, passage of an endoscope through a trans-
lumenal stent will enable the endoscopist to expand the frontier of
endoscopic intervention to structures outside of the gastrointes-
tinal tract.
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